Basilea antibiotic hit with complete response letter
This article was originally published in Scrip
Executive Summary
The US FDA has issued a complete response letter denying approval for Basilea Pharmaceutica and Johnson & Johnson's Zeftera (ceftobiprole) for the treatment of complicated skin and skin structure infections. In the letter, the agency questioned the integrity of the trial data.